Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

Non-small cell lung cancer (NSCLC) accounts for over 85% of lung cancers. Approximately 30-40% of East Asian adenocarcinoma patients harbor EGFR mutations. Third-generation EGFR-TKIs achieve a median PFS of about 20 months as first-line therapy, but resistance eventually develops. Studies like MARIPOSA-2 confirm that amivantamab combined with chemotherapy ± lazertinib or immunotherapy regimens (ivucitinib/sintilimab + bevacizumab + chemotherapy) can extend median PFS post-resistance from approximately 4 months to 6-8 months. As a third-generation TKI, befitinib has demonstrated PFS of 16-22 mo

Trial Details

NCT ID

NCT07181499

Phase

PHASE2

Sponsor

Betta Pharmaceuticals Co., Ltd.

Status

RECRUITING

Cancer Type

Adenocarcinoma Lung Cancer

Interventions

• Befotertinib
• Pemetrexed + Carboplatin

Locations (sample)

• Guangzhou, Guangdong, China|23.11667,113.25
• Zhuhai, Guangdong, China|22.27694,113.56778

Key Eligibility Criteria

• Age ≥18 years;
• Histologically or cytologically confirmed advanced or metastatic non-squamous NSCLC; and prior resistance to third-generation EGFR TKIs, with EGFR-…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →